| Outcome Measures: |
Primary: Percentage of Participants With Blood Pressure (BP) <140/85 mmHg (Systolic BP <140 mmHg and Diastolic BP <85 mmHg) by Clinic-Measured Sitting BP at Week 12, Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer., Week 12 | Secondary: Percentage of "Treatment-Naïve" Participants Reaching BP <140/85 mmHg, Treatment-naïve participants are defined as participants who have not received anti-hypertensive treatment for at least four weeks prior to screening. At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer., Up to Week 12|Percentage of Participants Treated With Calcium Channel Blocker (CCB) Before Baseline Reaching BP<140/85 mmHg, At each visit three serial BP measurements were determined while the participant was seated, with a sphygmomanometer., Weeks 6 and 12|Percentage of Participants Treated With Angiotensin Converting Enzyme (ACE) Inhibitors or Other Angiotensin Receptor Blockers (ARBs) Before Baseline Reaching BP <140/85 mmHg, At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer., Weeks 6 and 12|Percentage of Participants Treated With Thiazides Before Baseline Reaching BP <140/85 mmHg, At each visit three serial BP measurements were determined while the participant was seated, with a sphygmomanometer., Weeks 6 and 12|Percentage of "Treatment-Naïve" Participants Reaching BP <130/80 mmHg, Treatment-naïve participants are defined as participants who have not received anti-hypertensive treatment for at least four weeks prior to screening. At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer., Up to Week 12|Percentage of Participants Treated With CCB Before Baseline Reaching BP <130/80 mmHg, At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer., Weeks 6 and 12|Percentage of Participants Treated With ACE Inhibitors or Other ARBs Before Baseline Reaching BP <130/80 mmHg, At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer., Weeks 6 and 12|Percentage of Participants Treated With Thiazides Before Baseline Reaching BP <130/80 mmHg, At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer., Weeks 6 and 12|Percentage of Participants With Systolic Blood Pressure (SBP) <140 mmHg at Week 12, Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer., Week 12|Percentage of Participants With Diastolic Blood Pressure (DBP) <85 mmHg at Week 12, Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer., Week 12|Percentage of Participants With DBP <90 mmHg at Week 12, Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer., Week 12|Percentage of Participants With BP <130/80 mmHg at Week 12, Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer., Week 12|Percentage of Participants With SBP <130 mmHg at Week 12, Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer., Week 12|Percentage of Participants With DBP <80 mmHg at Week 12, Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer., Week 12|Percentage of Participants With BP <140/90 mmHg at Week 12, Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer., Week 12|Change From Baseline in Trough Sitting SBP at Week 12, At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer. Change from Baseline was estimated using an ANCOVA model with fixed effects, country, baseline hypertension therapy (BHT) and baseline SBP (or DBP) included as a covariate. A negative change from baseline indicates improvement., Baseline and Week 12|Change From Baseline in Trough Sitting SBP at Week 12 in "Treatment-Naïve" Participants, At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer. Change from Baseline was estimated using an ANCOVA model with fixed effects, country, baseline hypertension therapy (BHT) and baseline SBP (or DBP) included as a covariate. A negative change from baseline indicates improvement., Baseline and Week 12|Change From Baseline in DBP at Week 12, At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer. Change from Baseline was estimated using an ANCOVA model with fixed effects, country, BHT and baseline SBP (or DBP) included as a covariate. A negative change from baseline indicates improvement., Baseline and Week 12|Change From Baseline in DBP at Week 12 in "Treatment-Naïve" Participants, At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer. Change from Baseline was estimated using an ANCOVA model with fixed effects, country, BHT and baseline SBP (or DBP) included as a covariate. A negative change from baseline indicates improvement., Baseline and Week 12
|
| Locations: |
Hong Kong, Hong Kong, China|Changhua County, Taiwan|Kaohsiung City, Taiwan|Kaohsiung, Taiwan|Taichung, Taiwan|Tainan City, Taiwan|Taipei, Taiwan|Taoyuan County, Taiwan|Bangkok, Thailand|Chiang Mai, Thailand|Khon Kaen, Thailand|Pathumthani, Thailand
|
